Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus LEVOCETIRIZINE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus LEVOCETIRIZINE DIHYDROCHLORIDE.
BROMPHENIRAMINE MALEATE vs LEVOCETIRIZINE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Levocetirizine is a selective antagonist of peripheral histamine H1 receptors, blocking histamine-induced allergic responses by inhibiting H1 receptor activation in the gastrointestinal tract, blood vessels, and respiratory tract.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life: 7-11 hours in adults. Clinically, this supports once-daily dosing; may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Renal: 85% as unchanged drug (70%) and metabolites (15%); fecal: 13%; biliary: minimal (<2%).
Category C
Category A/B
Antihistamine
Antihistamine